Nanomedicine company developing radioenhancer therapies designed to improve the local effect of radiotherapy.
Independent editorial and sponsored coverage are visibly separated. Sponsored company reports carry a clear commercial-relationship disclosure and remain subject to the same sourcing, byline, date and correction standards as other newsroom reports.
All 24 patients completed treatment in the Phase 1 cohort, with investigators reporting no dose-limiting toxicities related to JNJ-1900 plus re-irradiation.
Read full report →Send verifiable public material, a factual correction or a news tip to the editorial desk. Submissions are reviewed independently and do not guarantee publication.
